Due Diligence in Life Science Transactions, 2nd Edition

How to prepare for business transactions in the life sciences, such as license agreements, venture investments, or corporate mergers

By Ian J. Mehr, Ph.D., MBA

Published: November, 2007

Due diligence is pivotal to success. McKinsey & Co recently found that nearly 90% of successful acquisitions were performed by companies with robust, documented due diligence procedures, compared to only 63% of those that experienced failed acquisitions.

Every business transaction involves due diligence. Due diligence is both essential and an enigma for someone just entering the field as either entrepreneur or manager.

Report Overview

D&MD's Guide to Due Diligence in Life Science Transactions, 2nd Edition provides a comprehensive overview on due diligence and a proven path to success for professionals working in the life sciences industry. This guide includes summaries of key investigation areas and critical questions to ask during the due diligence process. Also included are checklist tools readily employable in day-to-day business operations.

This guide will benefit the following:

* New business development professionals: Learn the broad issues in business transactions to be prepared to experience them first hand.

* Industry scientists: If you are recruited to be part of a due diligence team during a transaction or are interested in a career switch to business development this guide gives you all you need to know.

* Academic researchers: Those considering starting a business based on their own technology must understand and prepare for the inevitable questions that a venture capitalist or other investor will ask.

* C-level management: Professionals new in the life science industry-but with experience elsewhere-may need to get a grip on the unique issues in business transactions in the life sciences.

Receive answers to questions such as:

* How should due diligence be approached?

* What are the critical areas of due diligence in the life sciences?

* What materials should be requested for critical areas?

* What questions should be asked when reviewing provided materials?

* Where to find other materials and information?

About the Author: Ian J. Mehr, Ph.D., MBA, a principal with Golden Pine Ventures, LLC, serving as a Managing Director. Previously, Dr. Mehr served as Vice President of Business Development for Qualyst, Inc., a biotechnology company focused on novel and proprietary ADMET products that increase the efficiency and effectiveness of drug discovery and development.

November 007 Pages 74 PDF
Table of Contents
Price: $995.00 / GBP656.70